[{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"CYR-064","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Intranasal spray","sponsorNew":"Cyrano Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Remiges Ventures"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"CYR-064","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CYR-064","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Theophylline","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Theophylline","moa":"PDE3\/4","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Cyrano Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Theophylline","moa":"PDE3\/4\/A2B","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Cyrano Therapeutics \/ KYORIN Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ KYORIN Pharmaceutical"}]